The Democratic Party was badly ripped off by the consultant(s) who came up with the name for their new economic agenda, "A Better Deal," unveiled last week. After all, it is not hard to come up with a better deal than the reality TV show star president who is handing as much money as possible to the rich, while taking away people's health care and using his office to line the pockets of his family members.
The most encouraging part of what we have seen to date is the discussion of anti-trust policy. Since 1980, the leadership of the Democratic Party was largely in step with the Republicans in viewing anti-trust policy as passe'. The European Union went after Google over its practice of favoring advertisers in search results, the Obama administration did not. And when Facebook looked to use takeovers to eliminate potential competitors like Snapchat and WhatsApp, the Obama administration looked the other way.
In the outline of the Better Deal, the Democrats promise to go after mergers that give companies excessive market power, both in dealing with customers, but also in dealing with suppliers. This could limit the ability of a behemoth like Amazon to depress the pay of authors.
Other parts of the Better Deal are less encouraging. The discussion of drug prices seemed like it was written by people trying to pretend to do something, but who want to assure the pharmaceutical industry they are not really serious.
The original document called for a "special special [sic]" to deal with large drug price increases. It was corrected to "special office," but the typo was perhaps revealing of an effort to suggest complicated actions when the simple steps needed to rein in drug prices are already well-known.
Seventeen Democratic senators, including Bernie Sanders, Elizabeth Warren, Sherrod Brown and Kirsten Gillibrand, co-sponsored a bill that called for re-importation of drugs from countries with lower prices. It also called for a fund to buy out patents and for government funding of clinical drug trials. Both of these policies would allow new drugs to be sold at generic prices. This means the next great cancer drug might sell for a few hundred dollars instead of a few hundred thousand dollars.
Then we have the tax credit to businesses to cover the cost of training workers. This one plays to the idea that one of our biggest problems is workers not having the necessary skills.
While it would be good to have a better trained workforce, we don't actually see the most obvious sign of a skills shortage: rapidly rising wages for skilled workers. It is also not clear that a tax credit for businesses is the best way to give workers more skills, as opposed to more funding for community colleges and public universities.
This was a major theme of Bernie Sanders presidential campaign and was part of the motivation for his financial transactions tax (FTT) proposal. We know from WikiLeaks that even the top officials in the Clinton campaign took it seriously enough to consider a FTT themselves. But there is no mention of a FTT in the Better Deal, nor any other measures to rein in the financial sector.
This raises the central problem faced by the Democrats in setting out their agenda. The party has become dependent on campaign contributions from wealthy donors. Many of these are connected to the financial industry, which makes their reluctance to be too harsh on the industry understandable. Others come from the tech sector, which may also explain the lack of interest in prior years in pursuing anti-trust and the push by Democratic administrations for longer and stronger patent and copyright protection.